Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Monday, March 17, 2014 10:22:12 AM
Monday 17 March 2014
PETACH TIKVA, Israel, March 17, 2014 /PRNewswire/ -- Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel.
The company plans to conduct the Phase II study in Israel, Europe and the US and it will include 78 subjects that will be dosed with the drug as a second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The protocol has been approved by the IRB at the Rabin Medical Center, Petach Tikva, and the company intends to follow up with European and US submissions shortly. The study protocol was developed with the assistance of Dr. Keith Stuart, MD, Chairman, Department of Hematology and Oncology Professor of Medicine, Tufts University School of Medicine, a well-known internationally expert in Liver Cancer. This center will also participate in the study.
The US Food and Drug Administration (FDA) has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma. FDA orphan drug status grants various incentives for developing these drugs, including shortened approval procedures, tax breaks on R&D costs, and financing assistance. If the drug is the first to reach market, it also receives seven years exclusivity.
According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2 billion by 2015.
The company reported earlier that data from the Phase I/II study were published recently in The Oncologist, one of the leading journals in this field, and was presented at the 18th World Congress on Advances in Oncology. The company reported that the Phase I/II study data demonstrated that the trial objectives were successfully achieved, demonstrating a very favorable safety profile for CF102 in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis classes A and B. In addition, the median overall survival time was very encouraging given that most patients were treated in the second-line setting and some were Child-Pugh Class B. Another finding indicated that the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict the patients' reaction to treatment with CF102. Interestingly, one of the patients included in the Phase I/II study has been treated for 4 years with CF102 and is continuing to be treated, with CF102.
About CF102
CF102 is a small orally bioavailable drug which binds with high affinity and selectivity to the A3 adenosine receptor. The latter is highly expressed in tumor cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug. In our pre-clinical and clinical studies, CF102 induces a robust anti-tumor effect via de-regulation of the Wnt signaling pathway, resulting in apoptosis of liver cancer cells.
Recent MIGI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 09:48:55 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for August 2024 • GlobeNewswire Inc. • 09/16/2024 10:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 10:00:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 10:09:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 10:10:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 01:26:21 PM
- Mawson Infrastructure Group Expands to Ohio for AI/HPC Expansion • GlobeNewswire Inc. • 08/27/2024 12:50:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 12:48:56 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for July 2024 • GlobeNewswire Inc. • 08/22/2024 12:50:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 12:48:25 PM
- Mawson Infrastructure Group Inc. Reports Q2 2024 Financial Results • GlobeNewswire Inc. • 08/19/2024 09:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 09:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:57:21 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:30:02 PM
- Mawson Infrastructure Group Inc. to Join World Summit AI (Artificial Intelligence) in October 2024 • GlobeNewswire Inc. • 08/14/2024 12:30:18 PM
- Mawson Infrastructure Group Inc. Expands into AI and HPC Markets and Announces the Signing of AI/HPC Colocation Agreement for 20 MW • GlobeNewswire Inc. • 08/12/2024 12:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:45:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:35 PM
- Mawson Infrastructure Group Inc. to Present at the 2024 Gateway Conference in San Francisco, CA • GlobeNewswire Inc. • 08/06/2024 12:45:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 09:02:41 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2024 • GlobeNewswire Inc. • 07/18/2024 08:53:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:46:03 PM
- Mawson Infrastructure Group Announces Several Recent New Hires to Further Drive Transformation and Growth Initiatives • GlobeNewswire Inc. • 07/17/2024 08:45:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM